Navigation Links
Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

plus ribavirin was associated with improvement in sustained virologic response rates without increasing the toxicities associated with peginterferon and ribavirin.(7),(8) Romark is preparing to initiate phase III clinical trials of nitazoxanide plus peginterferon for treatment of CHC.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood.  A large majority of those infected do not show symptoms, but fatigue, abdominal pain and nausea can be common.  The current standard treatment of care, peginterferon and ribavirin, is effective in about half of all patients treated. Treatment outcomes vary based on a number of factors including genotype, viral load, genetic factors, stage of liver disease, co-infections and ability to adhere to treatment.  According to the Centers for Disease Control, HCV affects an estimated 3.2 million Americans.

About Romark Laboratories

Romark Laboratories, L.C. (www.romark.com) is a biopharmaceutical company committed to the discovery and development of innovative new small molecules for treating infectious diseases and cancers.  The Company is developing a new class of broad-spectrum antiviral drugs called the thiazolides. The first thiazolide, nitazoxanide, is an investigational new drug in late-stage clinical development for the treatment of chronic hepatitis C and influenza. Other new thiazolides are expected to enter clinical development in 2011.  Romark markets Alinia® (nitazoxanide) tablets, 500 mg and Alinia® (nitazoxanide) for Oral Suspension, 100 mg/5 mL in the United States.

About Intercell AG

Intercell AG is an innovative biotechnology company that de
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
2. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
3. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
4. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
5. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
6. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
7. Romark Laboratories Raises $18 Million in Institutional Financing
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
10. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
11. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... OAKS, Calif. , Oct. 17, 2014  Amgen ... of R. Sanders Williams , M.D., president of ... Mahley Distinguished Professor.  "We are pleased ... Amgen Board," said Robert A. Bradway , chairman ... and distinguished experience in academic medicine and his direct ...
(Date:10/17/2014)... , October 17, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced ... Monitor : North American Automated External ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report ... 2008-2018 analyzes the market of devices ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... October 20, 2014 Final Cut Pro X ... of the Citrus theme for FCPX filmmakers . , ... to describe the Citrus theme” Says Christina Austin, CEO of ... look so professional.” , Citrus comes with all the tools ... template are: four transitions for added style, a title screen ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... Visual Impact Frequency Training - a ... to the public generating a frenzied buzz of ... community. The commotion surrounding the program's launch has ... an investigative review. , "Many gym-goers are familiar ... known as a training 'plateau' where they are ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... ALEXANDRIA, Va., Sept. 24 - An editorial,published ... Dental Research (JDR),focuses on the global theme issue ... for Dental Research (IADR) President,Deborah Greenspan and IADR ... of Orofacial Sciences, School of Dentistry, The AIDS ...
... Companies Investing in R&D Shows Revenue Derived ... of Total Revenue in 2006, PHILADELPHIA and ... International Ltd. (CMR), a Thomson business, today,announced it ... an indispensable reference and business planning tool for,decision ...
... announced today that the U.S. Food and Drug ... 360(TM) Orbital Atherectomy System (OAS),for removing plaque blockages ... device offers a promising new alternative for treating ... Disease,PAD. The clearance follows the successful completion ...
... the Institute of Bioengineering and Nanotechnology (IBN), Institute of ... Singapore (GIS) have successfully developed a miniaturized device that ... flu (H5N1) virus. , If successfully commercialized, this ... surveillance of nascent avian flu epidemic. , According to ...
... The Iacocca Foundation and S.E.VEN, BOSTON, Sept. 24 ... has added finding a cure for diabetes and,alleviating world ... of The,Iacocca Foundation and S.E.VEN. "As communicators, we ... not driven by dollars, but by a commitment,to truly ...
... Md., Sept. 24 MedImmune, Inc. announced,today that ... to GlaxoSmithKline to support the development and construction ... vaccines. Reverse,genetics is a method by which viruses ... DNA. For potential pandemic influenza vaccines, reverse,genetics can ...
Cached Medicine News:Health News:Dental Researchers Participate in Global Awareness Initiative 2Health News:2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available 2Health News:2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available 3Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 2Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 3Health News:Lab-on-chip testing for 'bird flu' developed by Singapore scientists 2Health News:Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts 2Health News:MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production 2
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
Medicine Products: